Develop ophthalmic drugs for Stargardt disease and diabetic retinopathy. Create remote retinal monitoring devices for home use. Now — the numbers.
An investor who bought at the very peak is down 64% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
We do not hold enough financial data on this company to point to a strength.
The stock sits at $0.96. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Since the drop from its peak, buyer appetite hasn’t come back.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: revenue and profit, the growth trend, the balance sheet, earnings execution, the revenue breakdown.